Fosamax and Sildenafil Interaction: What Women Need to Know

What Is the Fosamax and Sildenafil Interaction, Exactly?

The short answer: there is no known direct drug-drug interaction between alendronate and sildenafil at the enzyme or transporter level. What does exist is a pharmacodynamic consideration. Sildenafil lowers blood pressure by inhibiting phosphodiesterase type 5 (PDE5), increasing cyclic GMP, and relaxing vascular smooth muscle. If you are a postmenopausal woman taking alendronate for osteoporosis and your clinician also prescribes sildenafil for pulmonary arterial hypertension (PAH), the blood-pressure effect of sildenafil warrants monitoring, particularly if you are also on antihypertensives.

Alendronate itself has no meaningful hemodynamic activity. It works in bone, not in blood vessels.

How Alendronate Works in Your Body

Alendronate is a nitrogen-containing bisphosphonate that binds to hydroxyapatite in bone and inhibits osteoclast-mediated bone resorption. The FDA-approved label for alendronate shows oral bioavailability of roughly 0.6 to 0.7 percent under fasting conditions, and the drug has virtually no hepatic metabolism. It is not a substrate, inhibitor, or inducer of cytochrome P450 enzymes. There is no CYP interaction with sildenafil to worry about.

Renal excretion handles elimination, with a terminal half-life exceeding 10 years because alendronate deposits in bone and is released only as bone turns over. This long skeletal half-life matters for pregnancy planning, discussed in the dedicated section below.

How Sildenafil Works

Sildenafil inhibits PDE5, the enzyme that degrades cyclic GMP in vascular smooth muscle. The result is vasodilation. The FDA label for sildenafil (Revatio) lists systemic hypotension as a key risk, particularly when combined with nitrates (absolutely contraindicated) or alpha-blockers. Sildenafil is metabolized primarily by CYP3A4 and secondarily by CYP2C9 in the liver, so it does interact with drugs that affect those enzymes, but alendronate is not one of them.

The standard PAH dose (Revatio) is 20 mg three times daily. The erectile-dysfunction dose (Viagra) is 25 to 100 mg as needed. The higher the dose, the more pronounced the blood-pressure effect.

Why This Question Comes Up for Women

Most published interaction references were built around male clinical trial populations. Women are asking this question for two distinct reasons.

Reason 1: Postmenopausal osteoporosis. Alendronate is one of the most prescribed drugs in postmenopausal women. According to a 2022 analysis in the Journal of Bone and Mineral Research, bisphosphonates remain first-line pharmacotherapy for women with a 10-year major osteoporotic fracture risk of 20 percent or higher on FRAX scoring. If a woman in this group also develops pulmonary arterial hypertension, or if she is prescribed sildenafil off-label for another reason, the combination appears.

Reason 2: Women with PAH in reproductive years. PAH disproportionately affects women. Registry data from the REVEAL registry show a female-to-male ratio of approximately 4:1 in idiopathic PAH. A younger woman with PAH who later develops premature menopause or glucocorticoid-induced osteoporosis may end up on sildenafil and alendronate simultaneously.

The clinically useful framing is this: think about the interaction by life stage, not just by drug name.

| Life Stage | Likely Reason for Alendronate | Likely Reason for Sildenafil | Interaction Concern | |---|---|---|---| | Reproductive years | Glucocorticoid-induced osteoporosis | Pulmonary arterial hypertension | Low to moderate; blood pressure monitoring | | Perimenopause | Early bone-density loss | PAH or off-label use | Low; discuss CV risk factors | | Postmenopause | Primary osteoporosis | PAH | Low; routine BP checks sufficient |

Pharmacokinetic Interaction: Is There One?

No. Alendronate bypasses hepatic metabolism entirely. Sildenafil is primarily a CYP3A4 substrate. Because alendronate does not touch CYP3A4, CYP2C9, P-glycoprotein, or any of the major metabolic pathways sildenafil depends on, there is no pharmacokinetic drug-drug interaction between the two agents.

CYP3A4 and Sildenafil

Sildenafil's plasma concentration is highly sensitive to CYP3A4 inhibitors. Co-administration with strong CYP3A4 inhibitors such as ritonavir can increase sildenafil AUC by eleven-fold, which is clinically significant. Alendronate produces no change in sildenafil plasma levels. You do not need a sildenafil dose adjustment based on alendronate use.

P-glycoprotein

Sildenafil is a P-gp substrate. Alendronate has very low oral absorption partly related to transport proteins, but it is not a P-gp inhibitor. The two drugs do not compete at that transporter in a way that has been shown to affect clinical outcomes.

What About Renal Function?

This is the one indirect area worth flagging. Alendronate is renally cleared and is contraindicated when creatinine clearance falls below 35 mL/min. Sildenafil clearance is also reduced in severe renal impairment (CrCl <30 mL/min), where starting doses should be 25 mg for erectile dysfunction indications. If you have chronic kidney disease, both drugs require dose review independently, and your clinician should evaluate whether alendronate remains appropriate at all.

Pharmacodynamic Interaction: The Actual Clinical Consideration

Although there is no PK interaction, the pharmacodynamic picture deserves respect. Sildenafil lowers systemic blood pressure. The Revatio prescribing information reports mean decreases in supine systolic and diastolic blood pressure of approximately 8.4 and 5.5 mmHg, respectively, after a 20 mg dose in healthy volunteers.

Alendronate does not lower blood pressure. So for most women, adding alendronate to an existing sildenafil regimen does not change hemodynamic risk.

The concern flips if sildenafil is being added to a woman who is already on multiple antihypertensives and happens to take alendronate. In that scenario, the sildenafil-antihypertensive interaction is the clinically meaningful one, and alendronate is a bystander.

When Blood Pressure Monitoring Makes Sense

If you are a postmenopausal woman with hypertension, starting sildenafil for PAH while already taking alendronate, your clinician should:

• Check a baseline seated blood pressure before starting sildenafil.
• Recheck blood pressure at the 20 mg three-times-daily starting dose after one to two weeks.
• Ask about positional dizziness, light-headedness, or palpitations.
• Review your full antihypertensive list before prescribing sildenafil.

Alendronate requires no dose adjustment based on sildenafil co-administration.

Sex-Specific Physiology: What Changes Across Your Life Stages

Postmenopausal Women (the Core Osteoporosis Group)

After menopause, estrogen loss accelerates bone turnover. The Menopause Society's 2023 position statement on osteoporosis endorses bisphosphonates as first-line treatment when fracture risk is elevated, and alendronate 70 mg once weekly is the most commonly initiated regimen. Women in this group are typically not using sildenafil for sexual dysfunction, as sildenafil is not approved for female sexual dysfunction. The overlap occurs almost entirely in the PAH context.

Postmenopausal women with PAH on Revatio (sildenafil 20 mg TID) who also take alendronate should have blood pressure checked at standard intervals. No special interaction protocol is required beyond standard PAH monitoring.

Women in Reproductive Years (Glucocorticoid-Induced Osteoporosis or Early-Onset Disease)

Younger women on long-term glucocorticoids for conditions like rheumatoid arthritis, lupus, or inflammatory bowel disease may receive alendronate to protect bone density. ACR guidelines recommend bisphosphonates for premenopausal women on glucocorticoids when their fracture risk crosses defined thresholds, though this decision is more complex in women who might become pregnant.

A younger woman with PAH who is also on glucocorticoids might plausibly be on both sildenafil and alendronate. The interaction concern remains low, but her overall cardiovascular status needs careful review before any new vasoactive drug is started.

Perimenopause

Bone density begins declining in the late perimenopause transition, sometimes two to three years before the final menstrual period. A study in the Journal of Clinical Endocrinology and Metabolism showed that perimenopausal women lose spinal bone mineral density at rates comparable to early postmenopause. If a perimenopausal woman is receiving sildenafil for PAH and her DEXA scan prompts a bisphosphonate conversation, the alendronate-sildenafil co-prescription is clinically reasonable with routine monitoring.

Pregnancy, Lactation, and Contraception: A Required Section

Alendronate in Pregnancy

Alendronate is FDA Pregnancy Category D, meaning there is positive evidence of human fetal risk. Animal studies demonstrate skeletal developmental toxicity. The alendronate FDA label states that the drug should not be used during pregnancy.

The clinical concern beyond the pregnancy category itself is the skeleton's long-term retention of bisphosphonates. Alendronate released from bone during pregnancy could theoretically cross the placenta. A systematic review published in Osteoporosis International identified 78 pregnancies with bisphosphonate exposure and found a low observed rate of fetal skeletal abnormalities, though the data are insufficient to declare safety.

Practical guidance: Women of reproductive potential should use reliable contraception while on alendronate. If pregnancy is planned, the case for stopping alendronate well in advance is reasonable, though no formal washout period is established given the drug's skeletal half-life measured in years. Discuss with your clinician at least six to twelve months before attempting conception.

Sildenafil in Pregnancy

Sildenafil's pregnancy status is complicated. It is not FDA-approved for use during pregnancy, but it has been studied off-label for obstetric conditions, including fetal growth restriction. The STRIDER trial published in The Lancet found that sildenafil did not improve fetal growth outcomes and was associated with higher rates of neonatal pulmonary hypertension in the treated group, which led to early termination. Women with PAH who are pregnant face a particularly high-risk scenario; obstetric and pulmonary specialists must co-manage this carefully.

Lactation

Alendronate transfer into breast milk has not been well studied. Given extremely low oral bioavailability, systemic infant exposure would likely be minimal, but no human lactation data confirm this. Sildenafil is present in breast milk in small amounts; one case report and pharmacokinetic modeling suggest infant dose is well below 1 percent of the maternal weight-adjusted dose, which is generally considered acceptable. The decision to continue either drug while breastfeeding requires individual risk-benefit assessment with your prescriber.

Contraception Requirements

If you are taking alendronate and are of reproductive age, you need effective contraception. This is not optional counseling. The drug's extended skeletal half-life means that simply stopping the drug weeks before conception attempts does not reliably clear fetal exposure risk.

Who This Drug Combination Is Right For, and Who Should Pause

Women Likely to Have No Clinically Meaningful Interaction

• Postmenopausal women taking alendronate 70 mg weekly for primary osteoporosis who are started on sildenafil 20 mg TID for PAH, without significant hypotension at baseline.
• Women with normal or well-controlled blood pressure, not on alpha-blockers or nitrates.
• Women whose renal function is adequate (CrCl >35 mL/min for alendronate, >30 mL/min for standard sildenafil dosing).

Women Who Need Extra Caution

• Women with low baseline blood pressure (systolic <100 mmHg). Adding sildenafil even at PAH doses may cause symptomatic hypotension.
• Women on three or more antihypertensive agents. The pharmacodynamic effect of sildenafil stacks with existing blood-pressure medication.
• Women with severe renal impairment, where both drugs require independent dose review or discontinuation.
• Premenopausal women actively trying to conceive. Alendronate should be re-evaluated before conception attempts.

Women for Whom Sildenafil Is Simply Not Indicated

Sildenafil is not approved by the FDA for female sexual dysfunction. Some clinicians prescribe it off-label for hypoactive sexual desire disorder (HSDD) or arousal disorder, but the evidence base is weak. A Cochrane review of PDE5 inhibitors for female sexual dysfunction found insufficient evidence to support routine use. A woman with osteoporosis asking whether she can combine Fosamax with sildenafil for sexual health reasons should know this distinction: the interaction risk is low, but the indication itself lacks strong evidence.

Monitoring and Practical Counseling Points

If you and your clinician decide the combination is appropriate, here is what to track:

Blood pressure. Check before starting sildenafil and two weeks after initiating the drug. Report light-headedness, fainting, or unusual fatigue.

Alendronate administration. Take alendronate on an empty stomach with 6 to 8 ounces of plain water, at least 30 minutes before any food, drink, or other medication. Remain upright for at least 30 minutes. Sildenafil timing does not interfere with alendronate absorption if you separate them from each other and from food.

Renal function. Annual creatinine and eGFR are reasonable in any woman on long-term alendronate, especially if she is also on sildenafil for PAH, since PAH itself can compromise right-heart output and renal perfusion over time.

Esophageal symptoms. Alendronate can cause esophageal irritation. Any difficulty swallowing, chest pain, or new heartburn should be reported promptly and may require switching to an IV bisphosphonate or a different drug class entirely.

DEXA scan intervals. The Menopause Society recommends repeat DEXA at one to two years after initiating bisphosphonate therapy to assess response, then every two years if stable.

What the Drug Interaction Databases Say (and What They Miss)

Standard clinical DDI databases such as Lexicomp and Micromedex typically rate alendronate-sildenafil as having no interaction or a theoretical interaction of minimal clinical significance. No published case reports in the medical literature document a serious adverse event from this combination in women.

The evidence gap is real. Women have been under-represented in both bisphosphonate and PDE5 inhibitor clinical trials. Most PDE5 inhibitor safety data come from trials in men with erectile dysfunction. The PAH sildenafil data (SUPER-1 trial) included women but were not powered to detect sex-specific interaction signals with concurrent bone medications. The SUPER-1 trial in CHEST journal showed that sildenafil 20, 40, and 80 mg TID improved six-minute walk distance in PAH, with a safety profile that did not specifically report interactions with bisphosphonates.

The honest clinical position: the interaction is not dangerous for most women, but the data confirming safety in women specifically are thin because the right trial has never been done.

Other Fosamax Drug Interactions That Matter More

If you are reviewing your full medication list, the following interactions with alendronate carry greater clinical weight than sildenafil:

• Calcium and antacids. Taken within 30 minutes of alendronate, they bind the drug in the gut and reduce absorption to near zero. Separate by at least 30 to 60 minutes.
• NSAIDs. Both NSAIDs and alendronate irritate the upper GI mucosa. The combination increases risk of esophageal and gastric ulcers. A case-control study in BMJ found that concurrent NSAID and oral bisphosphonate use was associated with upper GI complications.
• Aspirin. Similar GI mucosal risk applies, though the magnitude is smaller.
• Aminoglycosides. Theoretically additive hypocalcemia risk; rare in outpatient practice but worth noting if hospitalized.
• Estrogen therapy. Not an interaction in the adverse-effect sense. Combined bisphosphonate plus hormone therapy produces additive bone-density gains per a meta-analysis in JAMA, though combination use is not routine first-line practice.